Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$77 Mln
Revenue (TTM)
$145 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.8
Industry P/E
--
EV/EBITDA
-2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
36,593,200
CFO
$-465.24 Mln
EBITDA
$-797.56 Mln
Net Profit
$-777.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IGM Biosciences (IGMS)
| -79.2 | -6.6 | 11.4 | -85.4 | -63.8 | -52.4 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
IGM Biosciences (IGMS)
| -26.3 | -51.1 | -42.0 | -66.8 | 131.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IGM Biosciences (IGMS)
|
1.3 | 76.6 | 145.1 | -53.4 | -26.7 | -71.6 | -- | 0.8 |
| 5.4 | 242.8 | 0.1 | -53.5 | -138,120.8 | -18.8 | -- | 0.9 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc.... in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC. Read more
CEO, President & Director
Mr. Fred M. Schwarzer J.D.
CEO, President & Director
Mr. Fred M. Schwarzer J.D.
Headquarters
Mountain View, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of IGM Biosciences Inc (IGMS) is $1.27 (NASDAQ) as of 15-Aug-2025 09:30 EDT. IGM Biosciences Inc (IGMS) has given a return of -63.77% in the last 3 years.
Since, TTM earnings of IGM Biosciences Inc (IGMS) is negative, P/E ratio is not available.
The P/B ratio of IGM Biosciences Inc (IGMS) is 0.76 times as on 15-Aug-2025, a 81 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.89
|
7.68
|
|
2023
|
-2.02
|
2.45
|
|
2022
|
-3.51
|
-1.31
|
|
2021
|
-6.17
|
-2.80
|
|
2020
|
-34.40
|
-14.65
|
The 52-week high and low of IGM Biosciences Inc (IGMS) are Rs 22.50 and Rs 0.92 as of 03-Apr-2026.
IGM Biosciences Inc (IGMS) has a market capitalisation of $ 77 Mln as on 15-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in IGM Biosciences Inc (IGMS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.